Literature DB >> 34173079

Strong association of common variants in the miRNA-binding site of NOD2 gene with clinicopathological characteristics and disease activity of systemic lupus erythematosus.

Emran Esmaeilzadeh1, Mostafa Saghi1, Mehdi Hassani1, Saeideh Davar2, Behrang Alani3, Bahram Pakzad4, Sepideh Ghobakhloo5, Sharifeh Khosravi5, Mehrdad Nasrollahzadeh Sabet6.   

Abstract

INTRODUCTION/
OBJECTIVES: Systemic lupus erythematosus (SLE) is a multifactorial systemic autoimmune disease, in which genetic susceptibility plays a pivotal role. The nucleotide oligomerization domain 2 (NOD2) gene is one of the main regulators of chronic inflammatory conditions and could be involved in SLE pathogenesis. Single nucleotide polymorphisms (SNPs) in miRNA binding sites which are located in 3'UTR of the NOD2 gene could be associated with SLE risk by dysregulation of NOD2 expression. In the present study, we assessed the possible association between SNPs rs3135500 and rs3135499 in the NOD2 gene with SLE risk in the Iranian population.
METHODS: A case-control study using 110 SLE patients and 120 control subjects was undertaken to estimate rs3135500 (G > A) and rs3135499 (A > C) genotypes via real-time PCR high-resolution melting method (HRM).
RESULTS: No significant association was observed between allele and genotype frequencies of rs3135500 and rs3135499 polymorphisms and SLE risk in this population (P > 0.05). However, there was an obvious association between rs3135500 (A allele) with laboratory factors that are associated with disease activity (P < 0.05) and some clinical manifestations that are associated with disease severity such as neurological symptoms, skin manifestations, renal involvements, and higher serum concentration of creatinine (P < 0.05). Besides, rs3135499 (C allele) was correlated with renal involvement and also the concentration of creatinine (P < 0.05). Moreover, in the patients group, the risk alleles in these polymorphisms were associated with lower age of onset (P < 0.05).
CONCLUSIONS: Our results suggest a substantial association between NOD2 polymorphisms with clinicopathological characteristics and SLE disease activity. Key Points • Single nucleotide polymorphisms (SNPs) in miRNA binding sites which are located in 3'UTR of the NOD2 gene could be associated with SLE risk by dysregulation of NOD2 expression. • Our results suggested that two miRSNPs (rs3135500 and rs3135499) in the NOD2 gene were meaningfully correlated with clinicopathological characteristics and disease activity of SLE.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  NOD2 gene; Single nucleotide polymorphism; Systemic lupus erythematosus; miRNA

Mesh:

Substances:

Year:  2021        PMID: 34173079     DOI: 10.1007/s10067-021-05812-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

Review 1.  Pattern recognition receptors in immune disorders affecting the skin.

Authors:  Heleen D de Koning; Anna Simon; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Innate Immun       Date:  2012-03-06       Impact factor: 7.349

Review 2.  Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets.

Authors:  Hai Long; Xin Wang; Yongjian Chen; Ling Wang; Ming Zhao; Qianjin Lu
Journal:  Cancer Lett       Date:  2018-04-20       Impact factor: 8.679

Review 3.  Systemic lupus erythematosus.

Authors:  Arvind Kaul; Caroline Gordon; Mary K Crow; Zahi Touma; Murray B Urowitz; Ronald van Vollenhoven; Guillermo Ruiz-Irastorza; Graham Hughes
Journal:  Nat Rev Dis Primers       Date:  2016-06-16       Impact factor: 52.329

4.  Association of rs3135500 and rs3135499 Polymorphisms in the MicroRNA-binding Site of Nucleotide-binding Oligomerization Domain 2 (NOD2) Gene with Susceptibility to Rheumatoid Arthritis.

Authors:  Naeim Ehtesham; Behrang Alani; Deniz Mortazavi; Sara Azhdari; Taiebe Kenarangi; Emran Esmaeilzadeh; Bahram Pakzad
Journal:  Iran J Allergy Asthma Immunol       Date:  2021-04-17       Impact factor: 1.464

Review 5.  Genetic susceptibility to SLE: recent progress from GWAS.

Authors:  Yong Cui; Yujun Sheng; Xuejun Zhang
Journal:  J Autoimmun       Date:  2013-02-06       Impact factor: 7.094

Review 6.  The genetics of lupus: a functional perspective.

Authors:  Sandra G Guerra; Timothy J Vyse; Deborah S Cunninghame Graham
Journal:  Arthritis Res Ther       Date:  2012-05-29       Impact factor: 5.156

Review 7.  miRNAs in the Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Bo Qu; Nan Shen
Journal:  Int J Mol Sci       Date:  2015-04-28       Impact factor: 5.923

8.  Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus.

Authors:  Antonio Julià; Francisco Javier López-Longo; José J Pérez Venegas; Silvia Bonàs-Guarch; Àlex Olivé; José Luís Andreu; Mª Ángeles Aguirre-Zamorano; Paloma Vela; Joan M Nolla; José Luís Marenco de la Fuente; Antonio Zea; José María Pego-Reigosa; Mercedes Freire; Elvira Díez; Esther Rodríguez-Almaraz; Patricia Carreira; Ricardo Blanco; Víctor Martínez Taboada; María López-Lasanta; Mireia López Corbeto; Josep M Mercader; David Torrents; Devin Absher; Sara Marsal; Antonio Fernández-Nebro
Journal:  Arthritis Res Ther       Date:  2018-05-30       Impact factor: 5.156

9.  Mapping effector genes at lupus GWAS loci using promoter Capture-C in follicular helper T cells.

Authors:  Chun Su; Matthew E Johnson; Annabel Torres; Rajan M Thomas; Elisabetta Manduchi; Prabhat Sharma; Parul Mehra; Carole Le Coz; Michelle E Leonard; Sumei Lu; Kenyaita M Hodge; Alessandra Chesi; James Pippin; Neil Romberg; Struan F A Grant; Andrew D Wells
Journal:  Nat Commun       Date:  2020-07-03       Impact factor: 14.919

Review 10.  MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis.

Authors:  Mohammad Reza Karimzadeh; Maryam Zarin; Naeim Ehtesham; Sharifeh Khosravi; Mohsen Soosanabadi; Meysam Mosallaei; Peyman Pourdavoud
Journal:  Cancer Gene Ther       Date:  2020-03-23       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.